On Wednesday, Affymax Inc. and Takeda Pharmaceutical Co. announced that an advisory committee of the US Food and Drug Administration has decided to support Peginesatide and applauded its attributes for treating people living on dialysis due to chronic kidney disease, especially those who have developed anemia.

After the investors lost their right to get dividends for the fiscal year, Japanese stocks fell for the first ever time.

Drop of 1% was faced by Takeda Pharmaceutical Co., which has the highest dividend yield in the Nikkei 225 Stock Average. Whereas, Tokyo Gas Co., a gas utility, and Eisai Co., a drug maker, decreased more than 1.5%. Capcom fell down by 0.7% to 1,742 yen.

PPD, a drug development contractor said Friday it does not expects a $25 million payment from Japan-based Takeda Pharmaceuticals after that company raised concerns of a regulatory delay for the diabetes treatment candidate alogliptin.

According to reports by the Chicago Tribune, Takeda Pharmaceuticals' Uloric drug has received FDA's approval for treatment of gout - a painful joint disease causing inflammation, severe pain, and warmth in affected joints. Earlier, in November, FDA's arthritis advisory committee, I a 12-0 voting, had recommended approval of Uloric for chronic gout.